We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

125 hedge funds and large institutions have $404M invested in Design Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 29 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 29

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

13% more capital invested

Capital invested by funds: $358M → $404M (+$46.3M)

7% more funds holding

Funds holding: 117 → 125 (+8)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5.37% less ownership

Funds ownership: 66.97% → 61.59% (-5.4%)

Holders
125
Holders Change
+8
Holders Change %
+6.84%
% of All Funds
1.54%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
22
Increased
55
Reduced
29
Closed
13
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$4.59M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$15.3M
2
TECP
Trails Edge Capital Partners
Georgia
+$8.62M
3
DCM
Driehaus Capital Management
Illinois
+$5.72M
4
BBA
Baker Bros. Advisors
New York
+$3.57M
5
Goldman Sachs
Goldman Sachs
New York
+$2.37M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$26.8M
2
LGM
Logos Global Management
California
-$5.57M
3
FLSM
Frazier Life Sciences Management
California
-$4.89M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.31M
5
Invesco
Invesco
Georgia
-$1.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$2.57M +$46.8K +4,622 +2%
Citadel Advisors
27
Citadel Advisors
Florida
$2.46M -$2.31M -228,361 -50%
EC
28
Elmind Capital
New York
$2.21M – – –
AG
29
Algert Global
California
$2.18M +$172K +16,970 +9%
VFT
30
Vanguard Fiduciary Trust
Pennsylvania
$2.08M +$1.98M +195,658 New
Marshall Wace
31
Marshall Wace
United Kingdom
$1.61M -$754K -74,520 -33%
ACP
32
Acuta Capital Partners
California
$1.55M -$50.7K -5,006 -3%
Invesco
33
Invesco
Georgia
$1.51M -$1.66M -163,837 -54%
VPM
34
Vanguard Portfolio Management
Pennsylvania
$1.47M +$1.4M +138,565 New
SEI Investments
35
SEI Investments
Pennsylvania
$1.42M +$814K +80,473 +153%
N
36
Nuveen
North Carolina
$1.35M +$15.7K +1,555 +1%
LCM
37
Lynx1 Capital Management
Puerto Rico
$1.27M +$506K +50,000 +72%
TI
38
Trexquant Investment
Connecticut
$1.25M +$173K +17,144 +17%
Millennium Management
39
Millennium Management
New York
$1.16M -$728K -71,938 -40%
Raymond James Financial
40
Raymond James Financial
Florida
$1.15M -$13.3K -1,314 -1%
Jane Street
41
Jane Street
New York
$1.11M -$1.24M -122,610 -54%
VA
42
Verdad Advisers
Massachusetts
$982K +$934K +92,310 New
CM
43
Caption Management
Oklahoma
$923K +$877K +86,708 New
Squarepoint
44
Squarepoint
New York
$916K +$404K +39,975 +87%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$847K -$53.9K -5,330 -6%
EI
46
EAM Investors
California
$840K – – –
PWM
47
Palumbo Wealth Management
New York
$760K +$20.6K +2,031 +3%
American Century Companies
48
American Century Companies
Missouri
$698K +$79.3K +7,840 +14%
XT
49
XTX Topco
Cayman Islands
$648K +$260K +25,655 +73%
Canada Pension Plan Investment Board
50
Canada Pension Plan Investment Board
Ontario, Canada
$643K +$58.7K +5,800 +11%
1
2
3 4 5

DSGN Hedge Fund Activity: Q1 2026 in Review

125 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2026, worth a combined $404M — up 13% from $358M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new DSGN positions and 13 closed out — a net gain of 9 holders — while 55 added to existing stakes and 29 trimmed.

The largest buyer was RA Capital Management, adding an estimated $15.3M. The largest seller was Point72 Asset Management, cutting an estimated $26.8M.

  • 125 institutional investors held Design Therapeutics (DSGN) as of Q1 2026, up from 117 in Q4 2025.
  • Funds reported $404M of Design Therapeutics stock for Q1 2026, up 13% quarter-over-quarter.
  • 22 funds opened new Design Therapeutics positions in Q1 2026 and 13 closed out, a net change of +9 holders.
  • The largest Design Therapeutics buyer in Q1 2026 was RA Capital Management, an estimated $15.3M added.
  • The largest Design Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $26.8M sold.

Based on aggregated 13F filings for Q1 2026.